Skip to main
BNGO
BNGO logo

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics demonstrated strong growth in its second quarter of fiscal year 2025, achieving a 17% increase in the sale of nanochannel array flowcells, with 7,233 units sold compared to 6,165 in the same quarter of the previous year. The company's adjusted revenue, which excludes discontinued clinical services and focuses on consumables and software, increased by 11% year-over-year, with consumables and software revenues specifically rising by 16%. Additionally, Bionano's expectations for new OGM installations have improved for fiscal year 2025, projecting 20-25 installations, up from a previous estimate of 15-20, further indicating favorable operational momentum.

Bears say

Bionano Genomics faces significant financial challenges as reflected in the projected sales per share of $6.50 and net cash of $3.28 per share, indicating potential weaknesses in revenue generation. Moreover, there are notable risks including lower-than-expected market uptake and utilization of its products, which may hinder its growth prospects. Additionally, the company's reliance on securing further capital to sustain operations adds to the overall negative outlook, further complicating its financial stability.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.